作者
Marzia Del Re, Marcello Tiseo, Paola Bordi, Armida D'Incecco, Andrea Camerini, Iacopo Petrini, Maurizio Lucchesi, Alessandro Inno, Daniele Spada, Enrico Vasile, Valentina Citi, Giorgio Malpeli, Enrica Testa, Stefania Gori, Alfredo Falcone, Domenico Amoroso, Antonio Chella, Federico Cappuzzo, Andrea Ardizzoni, Aldo Scarpa, Romano Danesi
发表日期
2017/2/2
期刊
Oncotarget
卷号
8
期号
8
页码范围
13611
出版商
Impact Journals, LLC
简介
Aim
The aim of this study was to investigate the appearance of MUT KRAS during EGFR-TKI treatment and their contribution to drug resistance.
Methods
This study used cell-free circulating tumor DNA (cftDNA) to evaluate the appearance of codon 12 MUT KRAS and p. T790M EGFR mutations in 33 advanced NSCLC patients progressing after an EGFR-TKI.
Results
p. T790M EGFR was detected in 11 (33.3%) patients, MUT KRAS at codon 12 in 3 (9.1%) while both p. T790M EGFR and MUT KRAS codon 12 were found in 13 (39.4%) patients. Six patients (18.2%) were KRAS wild-type (WT KRAS) and negative for p. T790M EGFR. In 8 subjects paired tumor re-biopsy/plasma samples were available; the percent concordance of tissue/plasma was 62.5% for p. T790M EGFR and 37.5% for MUT KRAS. The analysis of time to progression (TTP) and overall survival (OS) in WT KRAS vs. MUT KRAS were not statistically …
学术搜索中的文章
M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini… - Oncotarget, 2017